Testing whether prochlorperazine can be safely used to move anti-cancer therapy targets temporarily to tumour cell surfaces.
- Conditions
- Squamous Cell CarcinomaCancer - Head and neck
- Registration Number
- ACTRN12619001051134
- Lead Sponsor
- niversity Of Queensland
- Brief Summary
In summary it was found that EGFR can be re-localised to the surface of tumours temporarily and reversibly in patients and the study moved forward to a Phase IB dose escalation study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 5
Histologically confirmed squamous cell carcinoma of head and neck mucosa
Tumour of any stage amenable to biopsy
Eastern Cooperative Oncology Group (ECOG) performance status equal to or greater than 2; On drugs that cause long QTc ; History of prolonged QT interval or prolonged QT interval on baseline ECG; Systolic blood pressure less than 90mmHg and/or diastolic blood pressure < 50 mmHg in two consecutive blood pressure readings within the 1 hour prior to study drug administration; Previous reaction to antipsychotic medications requiring medical intervention; Pregnant or breast feeding
Excluded if Parkinson’s disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method